Q-omics provides the consensus-scored ARL5AP2 profile across patient tissues and cancer cell-line models. ARL5AP2 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, ARL5AP2 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, ARL5AP2 RNA expression shows 10,151 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THYM, KIRC, and GBM as cancer lineages where ARL5AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL5AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL5AP2 survival associations across molecular data types. ARL5AP2 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL5AP2 RNA expression–survival associations across cancer types. High ARL5AP2 expression shows unfavorable associations in THYM, PAAD, UVM, PCPG and STAD, but favorable associations in OV. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for ARL5AP2 RNA expression.
This table summarizes ARL5AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ARL5AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL5AP2 shows lower tumor expression in KIRC. The KIRC box plot shows higher ARL5AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.015, t-test p = .038).
This table shows molecular features associated with ARL5AP2 in patient tissues and cancer cell lines. In patient samples, ARL5AP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
